Signals, Powered By EquityPandit
Zydus Cadila has got approval from the US health regulator for initiating phase II clinical trials of Sarolitazar, its new drug to treat high fat levels in body on account of diabetes, obesity and sedentary habits.
According to a statement by Zydus Cadila, “United States Food and Drug Administration (USFDA) has endorsed company’s plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia”.
It further added that this 12 week trial will evaluate three doses of Saroglitazar in the strengths of 1 mg, 2 mg, and 4 mg versus placebo.
